The Development of Ebolavirus Vaccines and Immunotherapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 253
Special Issue Editors
Interests: filovirus vaccine; antibody; Fc effector functions; NK cells
Special Issues, Collections and Topics in MDPI journals
Interests: zoonotic diseases; zoonoses; veterinary pathology; diagnosis; emerging infectious diseases; veterinary infectious diseases; veterinary clinical pathology; infectious disease control and prevention; infectious disease diagnostics; molecular diagnostics
Special Issue Information
Dear Colleagues,
Human Ebola disease is caused by an infection with either Ebola virus, Sudan virus, Taï Forest virus, or Bundibugyo virus. Ebola disease is relatively rare but can cause outbreaks with high case fatality rates, particularly in countries with limited health infrastructure or in areas of civil unrest. The largest outbreak of Ebola disease was caused by Ebolavirus and occurred in West Africa between 2014 and 2016, with over 28,000 cases and 11,000 fatalities. Ebola disease outbreaks have become more frequent because climate and environmental changes have resulted in increased interactions between humans and wildlife hosts, enabling spillover events. Therefore, it is important to continue the development of intervention strategies in at-risk countries to limit the occurrence and extent of future outbreaks.
Vaccines and immunotherapeutics play a key role in responses to epidemic threats and have been an important part of the response to Ebola disease outbreaks. However, questions remain about the optimal vaccination regiment and correlates of protection. Currently, there are also no licensed vaccines or therapies against the Sudan virus, Taï Forest virus, and Bundibugyo virus, although several candidate vaccines are in clinical development.
This Special Issue aims to collect reports of recent scientific knowledge and advances in vaccination and immunotherapeutics against Ebola disease. We are interested in a broad area of research, including advances in vaccine platform technologies, immunogenicity studies, preclinical efficacy studies (rodents to NHPs), and clinical trials that can inform future vaccination strategies against this disease.
Dr. Kyle L. O'Donnell
Dr. Lisa Hensley
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Ebola
- immunotherapeutics
- vaccine platforms
- immunogenicity
- animal studies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
